SG Americas Securities LLC Takes Position in PDS Biotechnology Co. (NASDAQ:PDSB)

SG Americas Securities LLC bought a new position in shares of PDS Biotechnology Co. (NASDAQ:PDSB) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,495 shares of the company’s stock, valued at approximately $52,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. BlackRock Inc. lifted its stake in PDS Biotechnology by 276.6% in the 2nd quarter. BlackRock Inc. now owns 1,732,918 shares of the company’s stock worth $8,717,000 after purchasing an additional 1,272,801 shares in the last quarter. Millennium Management LLC bought a new stake in shares of PDS Biotechnology in the fourth quarter worth about $5,958,000. State Street Corp lifted its position in shares of PDS Biotechnology by 345.7% in the second quarter. State Street Corp now owns 456,975 shares of the company’s stock worth $2,299,000 after buying an additional 354,442 shares in the last quarter. EAM Investors LLC bought a new position in PDS Biotechnology during the fourth quarter valued at approximately $4,362,000. Finally, Geode Capital Management LLC grew its holdings in PDS Biotechnology by 97.6% during the 2nd quarter. Geode Capital Management LLC now owns 577,394 shares of the company’s stock valued at $2,904,000 after buying an additional 285,141 shares in the last quarter. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Stock Performance

NASDAQ:PDSB opened at $2.64 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.33 and a current ratio of 4.33. The stock’s fifty day moving average is $4.61 and its 200 day moving average is $4.88. The firm has a market capitalization of $96.84 million, a PE ratio of -1.92 and a beta of 1.67. PDS Biotechnology Co. has a fifty-two week low of $2.59 and a fifty-two week high of $10.27.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Wednesday, March 27th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.05. On average, sell-side analysts anticipate that PDS Biotechnology Co. will post -1.55 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on PDSB. Cantor Fitzgerald reiterated an “overweight” rating on shares of PDS Biotechnology in a research report on Friday, January 12th. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a research report on Wednesday, March 27th. StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, March 16th. Finally, B. Riley restated a “buy” rating and set a $11.00 target price (down from $14.00) on shares of PDS Biotechnology in a research report on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $17.33.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.